Search Results
Adaptimmune's allogeneic or 'off-the-shelf' cell therapies.
Overcoming the challenges of off-the-shelf allogeneic cell therapies. With Dr. Jason Litten.
Off-the-shelf iPSC therapies for solid tumors
REPLAY of Adaptimmune’s First Live Virtual Event – Our Allogeneic Platform
Allogeneic, off-the-shelf, COVID-19-specific T-cells
Our Research: A Rich Cell Therapy Pipeline for the Future
Resisting immune rejection: engineered off-the-shelf T-cells
Adaptimmune
The current landscape of allogeneic CAR T-cell therapies
Autologous vs Allogeneic Cell Therapy
Adaptimmune ASGCT 2021
An insight into CTX130: a novel allogeneic CAR-T cell therapy